Protocolsβ€ΊGut Healing Protocol
BeginnerGut Health8 weeks

Gut Healing Protocol

Repair intestinal barrier integrity, reduce gut inflammation, and restore mucosal health in leaky gut, IBD, and post-antibiotic dysbiosis

Patient profile: Adults with irritable bowel syndrome, inflammatory bowel disease (Crohn's/UC in remission), leaky gut syndrome, or gastrointestinal side effects from NSAIDs/antibiotics

Want a personalised protocol?

Our AI generator builds a protocol tailored to your profile and goals.

Generate protocol β†’
⚠️

This protocol is an educational example only. It does not apply to your specific health situation. Medical supervision is required. Peptide therapy is not approved by regulatory bodies for many of the described indications.

Protocol Stack

BPC-157

Primary

Dose

250 mcg

Frequency

Twice daily oral (dissolved in water)

Timing

30 min before meals β€” morning and evening

Duration

8 weeks

KPV (Lys-Pro-Val)

Supporting

Dose

500 mcg

Frequency

Daily oral

Timing

With BPC-157 morning dose

Duration

8 weeks

Larazotide Acetate

Supporting

Dose

1.0 mg

Frequency

Three times daily oral

Timing

30 min before each meal

Duration

8 weeks

Monitoring Parameters

  • βœ“Stool calprotectin β€” baseline and week 8 (intestinal inflammation marker)
  • βœ“Zonulin (serum or stool) β€” baseline and week 8 (intestinal permeability marker)
  • βœ“GI symptom composite score (IBS-SSS or CDAI for Crohn's) β€” weekly
  • βœ“Stool microbiome analysis β€” optional, baseline and week 8
  • βœ“Nutritional markers: ferritin, B12, folate, D3 (often deficient with gut pathology)
  • βœ“Body weight (monitor for unintended loss)

Expected Outcomes

1

Days 3–7: Bloating and cramping often reduce quickly

2

Weeks 2–4: Stool consistency normalizing, frequency stabilizing

3

Weeks 4–6: Energy improving as nutrient absorption improves

4

Week 8: Calprotectin and zonulin reassessment β€” typically 40–70% reduction

5

Post-protocol: Maintenance with 1x daily BPC-157 for 4 weeks; then dietary review

Contraindications

  • βœ—Active GI bleeding β€” do not use BPC-157 until hemostasis confirmed
  • βœ—Malignancy of the GI tract
  • βœ—Severe active Crohn's disease (CDAI > 300) β€” requires gastroenterology co-management
  • βœ—Oral peptide absorption may be limited if intestinal damage is severe β€” consider SC route for BPC-157

Clinical Notes

Oral BPC-157 is preferred for gut pathology as it delivers the peptide directly to intestinal tissue. KPV is the active fragment of alpha-MSH with potent local anti-inflammatory and mucosal healing properties β€” specifically studied in colitis models. Larazotide blocks zonulin-mediated tight junction opening, directly addressing the core mechanism of leaky gut.

Case Study

Clinical Practice Example

Female, 36, post-antibiotic ulcerative colitis flare (fecal calprotectin 820 ΞΌg/g, zonulin 42 ng/mL, IBS-SSS 340). Started triple oral protocol. By week 2: abdominal pain reduced 50%. Week 8: calprotectin 198 ΞΌg/g, zonulin 19 ng/mL, IBS-SSS 90. Reported eating previously avoided foods without symptoms. Continued on maintenance BPC-157.

← Back to all protocols